Environment, Pathogens, and Host Interactions in Melioidosis
Official title: Decoding the Triad: the Interplay Between Environment, Pathogen, and Host in Melioidosis (DeEPH)
Run by University of Oxford · NCT07345910 · Data updated 2026-11-12
This study follows people with melioidosis and matched healthy controls to see how the disease develops and what factors influence outcomes over a year in Thailand, Laos, and Cambodia.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 2400 (estimated) |
| Sponsor | University of Oxford Academic / other |
| Locations | 3 sites (Siem Reap and 2 other locations) |
| Status | Recruiting |
| Started | August 19, 2026 |
| Main results expected | December 1, 2034 |
| Study ends | December 1, 2034 |
| Registry record updated | September 18, 2026 |
| Trial ID | NCT07345910 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 20 years and older with culture-confirmed melioidosis residing in the study areas for at least two years.
✕Probably not a fit
Individuals without melioidosis or those not meeting follow-up obligations may not gain direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicentre, longitudinal observational study enrolling about 1,000 patients with culture-confirmed melioidosis across three hospitals in Thailand, Lao PDR, and Cambodia. Participants are followed at six time points from admission through one year to collect data on demographics, comorbidities, exposures, treatments, adherence, and outcomes. For each patient, a healthy control matched by age, sex, and village is enrolled within two weeks to provide baseline blood samples for DNA and antibody profiling and to be followed short-term. An intensive subcohort in a high-risk Sandbox Village will monitor subclinical infections and environmental factors that may influence disease acquisition. The study aims to illuminate host-pathogen-environment interactions and improve understanding of recovery trajectories in melioidosis.
Why it matters
Potential benefit: Findings could improve risk stratification, understanding of recovery patterns, and inform public health strategies for melioidosis.
How similar studies have gone: Previous observational work in melioidosis has provided insights into risk factors and outcomes; this study builds on that by linking environmental and host factors across multiple sites.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria for melioidosis patients: * Age ≥20 years * Positive for Burkholderia pseudomallei from any clinical samples * Resident of the study area for at least two years, including the follow-up period * Willing to participate and give informed consent. Inclusion criteria for healthy controls: * Age ≥20 years * Currently healthy as judged by study doctor * Resident of the study area for at least two years, including the follow-up period * Willing to participate and give informed consent. Inclusion criteria for sandbox residents: * Age ≥20 years * Resident of the study area for at least two years, including the follow-up period * Willing to participate and give informed consent. Exclusion criteria for melioidosis patients: * Current tuberculosis (TB) or TB treatment within the past six months * Documented HIV infection or use of immunosuppressive therapy in the past 12 months Exclusion criteria for healthy controls: * History of melioidosis * Significant acute illness * Current fever or soft tissue infection Exclusion criteria for sandbox residents -N/A
Where it's running
-
Sunpasitthiprosong Hospital
Ubon Ratchathani, Thailand Recruiting -
Cambodia-Oxford Medical Research Unit (COMRU)
Siem Reap, Cambodia Not yet recruiting -
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
Vientiane, Laos Not yet recruiting
Study contacts
- Principal investigator: Kamolchanok Claire Chewapreecha, PhD — Mahidol Oxford Tropical Research Unit
- Study coordinator: Kamolchanok Claire Chewapreecha, PhD
- Email: claire@tropmedres.ac
- Phone: 662 203 6333
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Community spread of multiple infectious diseases in Cambodia from a One Health perspective
This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.
-
Newborn SMA Screening Service Evaluation
This project tests newborn SMA screening to see if it works well and is acceptable to families in the UK.
-
Prucalopride for low mood: testing a 5-HT4 receptor activator for cognition and sleep
This study tests whether prucalopride, a 5-HT4 receptor drug, can improve thinking and sleep in adults with low mood or major depressive disorder compared to a placebo.
-
Robotic-assisted tPA injection for retinal vein occlusion
This trial tests whether robot-assisted delivery of a clot-dissolving drug (tPA) into a blocked retinal vein can restore blood flow in people with central retinal vein occlusion.
-
Understanding heart artery disease using biomarkers and imaging in Oxford
Researchers in Oxford are testing how biomarkers and advanced imaging can help explain why some heart artery plaques are unstable and how this affects heart damage after a heart attack.
-
VTA real-time biofeedback with 7-Tesla MRI in depression
This study tests whether people with major depressive disorder can learn to modulate their brain's reward center (the VTA) using real-time feedback during 7-Tesla MRI sessions, to see if it changes mood and motivation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.